

38. The method of claim 37, wherein Factor X (FX) or Factor VII/VIIa (FVII/FVIIa) binding to the complex is inhibited.
39. The method of claim 37, wherein the antibody or fragment has the binding specificity for native human tissue factor about equal to or greater than H36.D2.B7 [ATCC HB12255].
40. The method of claim 38, wherein the antibody has identifying characteristics of H36.D2.B7 [ATCC HB-12255].
41. The method of claim 40, wherein the antibody is H36.D2.B7 [ATCC HB- 12255].
42. The method of claim 37, wherein the antibody is a monoclonal antibody.
43. The method of claim 42, wherein the antibody is chimeric or humanized.
44. The method of claim 43, wherein the antibody is chimeric and comprises a constant region of human origin.
45. The method of claim 43, wherein the humanized antibody comprises hypervariable regions of non-human origin.
46. The method of claim 37, wherein the antibody is a single chain antibody.
47. The method of claim 37, wherein the antibody comprises a sequence that has at least about 70 percent sequence identity to SEQ ID NO: 1.

48. The method of claim 47, wherein the antibody comprises a sequence represented by SEQ ID NO:2 or SEQ ID NO:4.

49. The method of claim 48, wherein the antibody comprises hypervariable regions that have at least 90 percent sequence identity to SEQ ID NOS. 5 through 10 inclusive.

50. The method of claim 49, wherein the antibody comprises hypervariable regions represented by SEQ ID NOS. 5 through 10 inclusive.

51. The method of claim 37, wherein the antibody comprises an immunological effector molecule.

52. The method of claim 51, wherein the immunological effector molecule is IgG1 or IgG3.

53. The method of claim 37, wherein the antibody is an immunologically active antibody fragment.

54. The method of claim 53, wherein the fragment is Fab, F(v), Fab' or F(ab)₂.

55. The method of claim 37, wherein the FX or FVII/FVIIa binding to the complex is inhibited by at least 80 percent in a standard in vitro binding assay.

56. The method of claim 37, wherein the FX or FVII/FVIIa binding to the complex is inhibited by at least 90 percent in a standard in vitro binding assay.

57. The method of claim 37, wherein the FX or FVII/FVIIa binding to the complex is inhibited by at least 95 percent in a standard in vitro binding assay.